Dr. Kwabena Gyabaah Owusu-Ansah , MD, PhD - First Affiliated Hospital Of Zhejiang University - Resident in Surgery

Dr. Kwabena Gyabaah Owusu-Ansah

MD, PhD

First Affiliated Hospital Of Zhejiang University

Resident in Surgery

Hangzhou, Zhejiang | China

Main Specialties: Gastroenterology, Hepatology, Surgery

Additional Specialties: Liver and Pancreatic Diseases, Gastrointestinal diseases

ORCID logohttps://orcid.org/0000-0002-6566-3222

Dr. Kwabena Gyabaah Owusu-Ansah , MD, PhD - First Affiliated Hospital Of Zhejiang University - Resident in Surgery

Dr. Kwabena Gyabaah Owusu-Ansah

MD, PhD

Introduction

Primary Affiliation: First Affiliated Hospital Of Zhejiang University - Hangzhou, Zhejiang , China

Specialties:

Additional Specialties:

Research Interests:


View Dr. Kwabena Gyabaah Owusu-Ansah ’s Resume / CV

Education

Jun 2019
Zhejiang University
Doctoral candidate, Hepatobiliary and Pancreatic surgery (PGY 4-6)
Anticipated completion: June, 2019
Jun 2016
Zhejiang University
M.S. (PGY1-3)
Master of Surgery
Feb 2013
Wenzhou Medical University
MBBS
Bachelor of Medicine and Bachelor of Science

Experience

Apr 2017
Mentorship
1 month working experience with Prof Jan Lerut Jan Lerut, MD, PhD | form president of ILTS
Zhejiang University International Hospital (Shulan Hospital)
Mar 2016
G20 Summit Medical English Training advisor for Doctors and Nurses
Train Doctors and Nurses in Medical English to equip them for the upcoming G20 Summit in Hangzhou
The First Affiliated Hosp of Zhejiang University
May 2015
Ad5-EBOV vaccine phase 1 trial
Research Assistant and Recruitment Manager
https://clinicaltrials.gov/ct2/show/NCT02401373
Nov 2013
General surgical Training with experience in assisting in liver transplant surgery (organ procurement, repair and transplant)
Residency Training
The First Affiliated Hosp of Zhejiang University

Publications

10Publications

412Reads

30Profile Views

88PubMed Central Citations

COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer.

Int J Oncol 2019 Aug 14;55(2):391-404. Epub 2019 Jun 14.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.

Pancreatic cancer is one of the most aggressive cancers worldwide with a high mortality rate. Prognosis remains poor even in this era of advanced medicine mainly due to early metastasis and invasion. The present study aimed to explore and validate predictors of distant metastasis and prognosis in pancreatic cancer. In our preliminary experiment, we established a novel metastatic pancreatic cancer cell line BxPC?M8 from parent BxPC?3 cells. Via whole genome sequencing, RT?qPCR, western blotting, migration and invasion assays, we initially found that BxPC?M8 shared similar biological characteristics to BxPC?3, but only differed in enhanced metastatic and invasive capabilities with a significant increase in collagen type VI ?1 chain (COL6A1) expression. Knockdown of COL6A1 via small interfering RNA led to a significant decrease in migration and invasion of BxPC?M8 cells, suggesting suppressed epithelial?mesenchymal transition. Furthermore, a significant increase in COL6A1 expression was observed in cancerous tissue compared with paracancerous tissue (40.7 vs 3.7, P=0.001). Additionally, its expression was observed to be significantly associated with distant metastasis and vascular invasion at the time of surgery. Multivariate analysis revealed that COL6A1 expression (hazard ratio 1.90, 95% confidence interval 1.04?3.47, P=0.037) is an independent predictor of overall survival (OS). The median OS observed for COL6A1+ and COL6A1? patients was found to be 8±4 and 14±7 months (P=0.021), respectively. Of note, we identified that COL6A1 expression in tissue samples was associated with significantly reduced OS (P=0.001), demonstrating that COL6A1 may serve an important role in the metastatic process and could be considered as a predictor of poor outcomes in patients with pancreatic cancer. In addition, our findings suggest that COL6A1 could be an indicator of distant metastasis and a valid prognostic predictor in such patients; however, further investigation is required.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2019.4825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615918PMC
August 2019
104 Reads
3.571 Impact Factor

Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma.

Am J Cancer Res 2018 1;8(7):1297-1306. Epub 2018 Jul 1.

Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou 310000, Zhejiang Province, China.

The prognosis of advanced hepatocellular carcinoma (HCC) patients remains extremely poor, partially due to the development of acquired resistance to sorafenib and chemotherapy. Cabazitaxel, a semisynthetic taxane, has been approved for the therapy of docetaxel-resistant prostate cancer. However, no studies have been performed on the effect of cabazitaxel on HCC, and whether cabazitaxel remains sensitive in chemotherapy-resistant and sorafenib-resistant HCC cells is not clear. Our results demonstrate that cabazitaxel is highly toxic to HCC cell lines in a time- and dose-dependent manner by inducing G2/M phase arrest and apoptosis in vitro. Cabazitaxel also significantly suppresses HCC tumor growth in vivo. In chemotherapy-resistant HCC cell Huh-TS-48 with P-gp-overexpression, cabazitaxel shows less cross-resistant to other chemotherapeutic agents. The resistance fold of cabazitaxel, doxorubicin, paclitaxel, docetaxel and vinorelbine is 1.53, 8.60, 38.58, 15.53 and 18.06 respectively. Furthermore, sorafenib-resistant HCC cell SK-sora-5 is still sensitive to cabazitaxel. The IC50 values of cabazitaxel after 72 h exposure for parental cell SK-hep-1 and resistant cell SK-sora-5 are 0.84 and 0.73 nM. The results indicate that cabazitaxel is a potential agent to treat HCC after developing chemotherapy resistance caused by overexpression of P-gp and acquired resistance to sorafenib, and might improve prognosis in advanced HCC patients.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079161PMC
July 2018
23 Reads
2 Citations
4.737 Impact Factor

Intra-Hepatic Splenosis With Cavernous Splenic Hemangioma in a Post Splenectomy Patient: A Case Report

J Clin Med Case Stud. 2017 March

Research and Reviews: Journal of Clinical and Medical Case Studies

An Intrahepatic mass was found in a 65 year old Chinese female who came to our center for a routine ultrasound exam. MRI showed a lesion in her left lobe of the liver. Surgical records revealed a history of splenomegaly in conjunction with cirrhosis due to hepatic schistosomiasis, for which she underwent surgery (splenectomy) at age 20. On abdominal computed tomography scan, a 4.2 × 5.6 cm sized focal bulging mass at the left lobe of the liver was noted occupying segments 2 and 3 (Couinaud classification). A partial hemi resection of the liver segments 2 and 3 was performed under laparoscopy and specimen was sent for pathological analysis. Frozen intraoperative section confirmed splenic tissue as opposed to liver tumor. Further pathologic assessment revealed normal splenic tissue adjacent to liver tissue with a cavernous hemangioma and small focal necrotic lesions. The patient was diagnosed with hepatic splenosis with cavernous hemangioma within the spleen. The spleen was reported functional on histochemical analysis.

View Article
April 2017

2 Citations

23 Reads

Central pancreatectomy for pancreatic schwannoma: A case report and literature review.

World J Gastroenterol 2016 Oct;22(37):8439-8446

Shao-Yan Xu, Kwabena Gyabaah Owusu-Ansah, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng, Wei-Lin Wang, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v22.i37.8439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055874PMC
October 2016
36 Reads
4 Citations
2.370 Impact Factor

Clinicopathological features of 11 Epstein-Barr virus-associated intrahepatic cholangiocarcinoma at a single center in China.

Medicine (Baltimore) 2016 Oct;95(40):e5069

aDepartment of Pathology bDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery cKey Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health dKey Laboratory of Organ Transplantation eCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Province, Hangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000005069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059078PMC
October 2016
48 Reads
1 Citation
5.723 Impact Factor

Chelerythrine ameliorates acute cardiac allograft rejection in mice.

Transpl Immunol 2016 09 19;38:78-83. Epub 2016 Jul 19.

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Province, Hangzhou, China; Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Zhejiang Province, Hangzhou, China; Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trim.2016.07.003DOI Listing
September 2016
50 Reads
1.832 Impact Factor

Expression and Critical Role of Interleukin Enhancer Binding Factor 2 in Hepatocellular Carcinoma.

Int J Mol Sci 2016 Aug 22;17(8). Epub 2016 Aug 22.

Department of Hepatobiliary Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms17081373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000768PMC
August 2016
47 Reads
3 Citations
2.862 Impact Factor

Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma.

J Exp Clin Cancer Res 2015 Jun 28;34:67. Epub 2015 Jun 28.

Department of Hepatobiliary Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.

Background: Hypoxia is a common feature of solid tumors, including HCC. And hypoxia has been reported to play an important role in HCC progression. However, the potential mechanism of miRNAs in hypoxia mediating HCC progression still remains unclear.

Methods: The HCC cells were cultured in the atmosphere of 1 % oxygen to induce hypoxia. The microRNA microarray was employed to search for the hypoxia-inducible miRNAs. RT-PCR, western blot and immunohistochemistry were used to detect the RNA and protein levels. HUVEC were applied to explore the angiogenesis level.

Results: We found that miR-182 was upregulated in the hypoxia-based microarray. We then revealed that miR-182 was also significantly increased in the HCC tissues compared to the corresponding normal tissues. In vitro capilliary tube formation assays showed that the miR-182 promoted angiogenesis. RASA1 was demonstrated as the direct target of miR-182. In addition, the suppression of RASA1 phenocopied the pro-angiogenesis effects of miR-182. Besides, RASA1 was also decreased in the hypoxia HCC cells while the inhibition of miR-182 partially restored the level of RASA1.

Conclusions: Our data showed that hypoxia regulated the expression of miR-182 and RASA1 to promote HCC angiogenesis.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-015-0182-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493986PMC
June 2015
63 Reads
32 Citations
5.646 Impact Factor

MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2.

J Transl Med 2014 Sep 22;12:259. Epub 2014 Sep 22.

Background: The deregulation of microRNAs has been reported to play a pivotal role in hepatocellular carcinoma (HCC). MiR-126-3p has been reported to be associated with poor prognosis in HCC. However the underlying mechanism of miR-126-3p in HCC remains unclear.

Methods: The expression levels of miR-126-3p in HCC tissues and cells were detected by RT-PCR. Transwell assay and capillary tube formation assay were applied to assess the metastasis and angiogenesis in vitro. Nude mice subcutaneous tumor model was used to perform in vivo study. Dual- luciferase reporter assay was conducted to confirm the direct binding of miR-126-3p and target genes. The changes of biomarker protein levels were examined by western blot and Immunohistochemistry.

Results: We observed that the miR-126-3p expression levels in HCC tissues and cells were significantly down-regulated. Through gain- and loss- of function studies, we showed that miR-126-3p dramatically inhibited HCC cells from migrating and invading extracellular matrix gel and suppressed capillary tube formation of endothelial cells in vitro. Furthermore, overexpression of miR-126-3p significantly reduced the volume of tumor and microvessel density in vivo. LRP6 and PIK3R2 were identified as targets of miR-126-3p. Silencing LRP6 and PIK3R2 had similar effects of miR-126-3p restoration on metastasis and angiogenesis individually in HCC cells. Furthermore, the miR-126-3p level was inversely correlated with LRP6 and PIK3R2 in HCC tissues. In addition, the rescue experiments indicated that the metastasis and angiogenesis functions of miR-126-3p were mediated by LRP6 and PIK3R2.

Conclusion: Our results demonstrates that deregulation of miR-126-3p contributes to metastasis and angiogenesis in HCC. The restoration of miR-126-3p expression may be a promising strategy for HCC therapy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-014-0259-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189615PMC
September 2014
22 Reads
42 Citations
4.098 Impact Factor

Ischemic preconditioning improves liver tolerance to congestion-reperfusion injury in mice.

J Surg Res 2014 Jun 5;189(1):152-8. Epub 2014 Feb 5.

Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou, Zhejiang Province, China; Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2014.01.061DOI Listing
June 2014
19 Reads
2 Citations
1.940 Impact Factor

Top co-authors

Shusen Zheng
Shusen Zheng

Zhejiang University

8
Lin Zhou
Lin Zhou

The First Affiliated Hospital of Zhengzhou University

6
Haiyang Xie
Haiyang Xie

Key Lab of Combined Multi-Organ Transplantation

5
Zhen Lv
Zhen Lv

Zhejiang University

3
Chaofeng Ding
Chaofeng Ding

First Affiliated Hospital

3
Chengli Du
Chengli Du

First Affiliated Hospital

3
Ke Sun
Ke Sun

Beijing Normal University

2
Hui Chen
Hui Chen

Key Lab for Agro-product Processing and Quality Control of Nanchang City

2
Heng Xiao
Heng Xiao

Yunnan University

2
Yang Tian
Yang Tian

Tongji University

2